Indian pharmaceutical companies have exported more than 320 million pills of tapentadol—a synthetic opioid painkiller—to West African nations over a three-year period, despite the drug never receiving regulatory approval in the receiving countries, according to an investigation published by Bellingcat.

The findings, released Thursday, raise serious questions about pharmaceutical supply chain oversight and the potential for diversion of controlled substances in regions with limited regulatory infrastructure. Tapentadol, marketed under brand names including Nucynta, is a Schedule II controlled substance in the United States due to its high potential for abuse and dependence.

Scale of Shipments Raises Alarm

The volume of pills shipped between 2023 and 2026 represents an extraordinary quantity for markets where the medication has no legal authorization for use. According to Bellingcat's reporting, the shipments originated from Indian pharmaceutical manufacturers, though the investigation did not specify which companies were involved or which West African nations received the bulk of the supply.

India has emerged as a global pharmaceutical manufacturing hub, producing an estimated 20 percent of the world's generic medicines by volume. The country's pharmaceutical sector operates under regulations that permit export of medications that may not be approved for domestic sale, a policy intended to provide affordable medicines to developing nations.

However, this regulatory framework has created potential vulnerabilities. When medications are exported to countries lacking robust pharmaceutical oversight, the risk of diversion into illicit markets increases substantially.

Tapentadol's Medical Profile and Abuse Potential

Tapentadol was developed as a dual-action pain reliever, combining opioid receptor activation with norepinephrine reuptake inhibition. It was approved by the U.S. Food and Drug Administration in 2008 for moderate to severe acute pain and later for chronic pain conditions including diabetic neuropathy.

While pharmaceutical companies initially positioned tapentadol as having lower abuse potential than traditional opioids like oxycodone, subsequent research and clinical experience have demonstrated significant risks. The drug produces euphoria similar to other opioids and carries risks of respiratory depression, physical dependence, and fatal overdose when misused.

The Drug Enforcement Administration classified tapentadol as Schedule II—the same category as morphine, fentanyl, and oxycodone—reflecting its high potential for abuse despite legitimate medical applications.

West Africa's Pharmaceutical Regulatory Gap

West African nations have struggled with pharmaceutical regulation amid limited resources and technical capacity. Many countries in the region lack comprehensive drug approval processes comparable to those in Europe or North America, creating opportunities for both counterfeit medications and unauthorized pharmaceutical products to enter local markets.

The absence of regulatory approval for tapentadol in these markets means physicians have not been trained in its appropriate use, pharmacies lack guidance on dispensing protocols, and healthcare systems have no monitoring mechanisms to track prescriptions or identify problematic use patterns.

This regulatory vacuum creates conditions where large quantities of a potent opioid can circulate without the safeguards typically required for controlled substances—including prescription requirements, dispensing limits, and abuse monitoring programs.

Global Opioid Crisis Expands Beyond North America

While opioid addiction and overdose deaths have been most extensively documented in North America, public health experts have warned that the crisis is expanding globally. The United Nations Office on Drugs and Crime has noted increasing non-medical use of pharmaceutical opioids in Africa, Asia, and other regions.

The pharmaceutical industry's role in this expansion has come under scrutiny. In the United States, major drug distributors and manufacturers have faced billions of dollars in legal settlements for their role in fueling the opioid epidemic through aggressive marketing and inadequate monitoring of suspicious orders.

The shipment of hundreds of millions of opioid pills to markets without regulatory approval suggests similar patterns may be emerging in regions with less capacity to identify and respond to pharmaceutical supply chain abuses.

Questions of Accountability and Oversight

The Bellingcat investigation highlights gaps in international pharmaceutical oversight that allow controlled substances to flow across borders with limited accountability. While the investigation documented the scale of shipments, questions remain about the distribution chain once pills arrive in West Africa.

Pharmaceutical exports are subject to various international frameworks, including the International Narcotics Control Board's monitoring of controlled substances. However, enforcement mechanisms vary widely, and companies shipping to countries with weak regulatory systems face limited consequences for questionable export practices.

Indian regulatory authorities have faced previous criticism for insufficient oversight of pharmaceutical exports. The country's drug approval system operates separately from export licensing, allowing companies to manufacture and ship products abroad that may not meet the standards required for domestic sale or use in more regulated markets.

Public Health Implications

The introduction of 320 million doses of an unapproved synthetic opioid into West African markets carries significant public health implications. Without proper medical supervision, prescription controls, or abuse prevention programs, these medications may contribute to increased rates of opioid dependence and overdose deaths in regions already facing substantial healthcare challenges.

Public health infrastructure in many West African nations remains focused on infectious diseases, maternal health, and malnutrition. The emergence of pharmaceutical opioid misuse would require new clinical expertise, treatment capacity, and monitoring systems that currently do not exist in many countries.

The investigation underscores the need for stronger international cooperation on pharmaceutical regulation and export controls, particularly for controlled substances with high abuse potential. As the global pharmaceutical supply chain becomes increasingly complex, the challenge of preventing diversion while ensuring access to essential medicines will require coordinated action across manufacturing, regulatory, and healthcare systems.